Status:
UNKNOWN
Interleukin and Autoantibodies in Myasthenia Gravis.
Lead Sponsor:
Assiut University
Conditions:
Myasthenia Gravis
Eligibility:
All Genders
18-60 years
Brief Summary
Myasthenia gravis is a B-cell-mediated autoimmune disorders causing muscle weakness due to defective synaptic transmission at the neuromuscular junction caused by autoantibodies to acetylcholine recep...
Detailed Description
Follicular T cells play a vital role during autoimmune disorders. The enhanced number or activation of these cells results in hyperproliferation of autoreactive B cells and overproduction of antibodie...
Eligibility Criteria
Inclusion
- Clinical Diagnosis of Myasthenia Gravis.
- Willingness to sample collection.
Exclusion
- History of chronic psychiatric or neurological disorder other than Myasthenia Gravis that can produce weakness or fatigue.
- Severe systemic illness affecting life-expectancy ( chronic liver or kidney diseases).
- History of autoimmune diseases, connective tissue diseases, , or genetic diseases.
- Patients on large dosage of immune-suppressive treatment or Intravenous immunoglobulin in the recent 3 months.
Key Trial Info
Start Date :
July 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT05301153
Start Date
July 1 2022
End Date
December 1 2024
Last Update
May 3 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.